The report Global Human Microbiome Market by Product (Probiotics, Prebiotics, Food, Diagnostic Tests, Drugs), Application (Diagnostic, Therapeutic), and Region (North America, APAC, Europe, and LAMEA). With a market size of USD 88.06 Mn in 2020, the Global Human Microbiome Market Size will grow to USD 1318.72 Mn by 2030 with a CAGR of 31.08 %.
To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/human-microbiome-market
Key Factors that are expediting the Market growth
The high coincidence of disease, Government investment in R&D infrastructure and Healthcare facilities, mergers & collaborations, a rise in venture capital investments, a rise in the incidences of lifestyle-related diseases and autoimmune disorders in healthcare in the region. a growing number of drug development processes, and a growing number of research activities in this region
By Product, the Drugs category dominates the market. \
The significant proportion of this segment can be attributed to the growing number of human microbiome-based medicinal products in clinical trials as well as increased funding for the development of microbiome-based pharmaceuticals.
By Application, the Diagnostic Centres dominated the market comprehensively.
By Application, the Diagnostics sector is expected to show sheer Dominance.
The Diagnostics segment leads the market due to scientific and technological advancements in human genome mapping and the emergence of omics technologies.
THE REGION OF NORTH AMERICA SIGNIFICANTLY DOMINATED THE MARKET
The Dominance is because of the robust healthcare facilities and expanded investment in the development of sophisticated technology.
Because of increased awareness, more government initiatives, an increase in medical tourism, and increased R&D in the region, Asia-Pacific is expected to develop at the quickest rate.
IMPORTANT MARKET PLAYERS:
The significant players covered in the Global Human Microbiome Market include-- Yakult Honsha Co., AOBiome, Enterome Biosciences SA, Metabiomics Corp. (BioSpherex LLC),
Microbiome Therapeutics LLC, Osel, Inc., Rebiotix, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Inc., Vedanta Biosciences, 4D PharmaDu Pont De Nemours and Co.Merck & Co. Ferring Pharmaceuticals
Recent Developments